Skip to main content

Table 2 Baseline characteristics of the Survivors and Non-survivors groups

From: Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database

Characteristic

Overall

Survivors

Non-survivors

P-value

(N = 1618)

(N = 1462)

(N = 156)

Age, years

68.05 (14.05)

67.31 (14.08)

74.97 (11.74)

 < 0.001

Male, n (%)

1054 (65.14)

963 (65.87)

91 (58.33)

0.060

BMI, kg/m2

29.60 (14.85)

29.79 (15.50)

27.93 (6.37)

0.256

SOFA score

3.00 (2.58)

2.70 (2.26)

5.80 (3.50)

 < 0.001

SIRS score

2.43 (1.05)

2.35 (1.04)

3.11 (0.92)

 < 0.001

APSIII

37.29 (17.14)

35.03 (14.58)

58.44 (23.72)

 < 0.001

SAPSII

32.45 (12.62)

30.72 (11.04)

48.68 (14.81)

 < 0.001

Comorbidities, n (%)

 Heart failure

651 (40.23)

574 (39.26)

77 (49.36)

0.014

 Hypertension

866 (53.52)

793 (54.24)

73 (46.79)

0.076

 Atrial fibrillation

401 (24.78)

330 (22.57)

71 (45.51)

 < 0.001

 Dyslipidemia

420 (25.96)

386 (26.40)

34 (21.79)

0.212

 Diabetes

484 (29.91)

436 (29.82)

48 (30.77)

0.806

 Respiratory failure

183 (11.31)

119 (8.14)

64 (41.03)

 < 0.001

 AKIa

830 (51.30)

707 (48.36)

123 (78.85)

 < 0.001

 CKD

179 (11.06)

152 (10.40)

27 (17.31)

0.009

 AMI

1126 (69.59)

1022 (69.90)

104 (66.67)

0.403

 PCI

1127 (69.65)

1058 (72.37)

69 (44.23)

 < 0.001

 CABG

186 (11.50)

177 (12.11)

9 (5.77)

0.018

Laboratory tests

 WBC, K/uL

11.76 (5.04)

11.57 (4.91)

13.52 (5.80)

 < 0.001

 Lymphocyte, %

15.24 (9.92)

15.73 (10.09)

11.62 (7.73)

 < 0.001

 Neutrophil, %

77.80 (12.16)

77.43 (12.05)

80.48 (12.74)

0.006

 RBC, m/uL

4.17 (0.68)

4.19 (0.68)

4.04 (0.66)

0.009

 Platelet, K/uL

250.27 (96.86)

250.25 (95.37)

250.45 (110.24)

0.981

 Hemoglobin, g/dL

12.67 (2.07)

12.73 (2.07)

12.08 (1.97)

 < 0.001

 Serum potassium, mEq/L

4.22 (0.77)

4.19 (0.75)

4.51 (0.88)

 < 0.001

 Serum sodium, mEq/L

138.23 (4.00)

138.26 (3.86)

137.94 (5.16)

0.346

 TC, mg/dL

161.20 (46.30)

162.37 (45.83)

149.09 (49.49)

0.001

 TG, mg/dL

132.82 (89.64)

133.13 (88.04)

129.92 (103.74)

0.670

 LDL, mg/dL

90.99 (39.95)

91.97 (39.50)

80.79 (43.19)

0.002

 HDL, mg/dL

45.05 (14.21)

45.08 (13.90)

44.74 (17.17)

0.790

 HbA1c, %

6.45 (1.42)

6.46 (1.44)

6.31 (1.15)

0.413

 Glucose, mg/dL

165.39 (86.07)

162.23 (84.14)

195.18 (97.85)

 < 0.001

 Albumin, g/dL

3.49 (0.58)

3.54 (0.54)

3.16 (0.70)

 < 0.001

 UCr, mg/dL

95.46 (65.61)

97.70 (66.32)

86.57 (62.36)

0.215

 SCr, mg/dL

1.27 (1.11)

1.22 (1.08)

1.67 (1.31)

 < 0.001

 BUN, mg/dL

24.30 (15.87)

23.26 (15.17)

34.04 (18.78)

 < 0.001

 TyG index

9.14 (0.71)

9.12 (0.71)

9.35 (0.73)

 < 0.001

  1. BMI body mass index, SOFA sequential organ failure assessment, SIRS systemic inflammatory response syndrome, APSIII acute physiology score III, SAPSII simplifed acute physiological score II, AKI acute renal injury, CKD chronic kidney disease, AMI acute myocardial infarction, PCI, percutaneous coronary intervention, CABG, coronary artery bypass grafting, WBC white blood cell, RBC red blood cell, TC total cholesterol, TG triglyceride, LDL low-density lipoprotein, HDL high-density lipoprotein, HbA1c hemoglobin A1c, UCr urine creatinine, SCr serum creatinine, BUN blood urea nitrogen, TyG index triglyceride glucose index
  2. aAKI was defined according to KDIGO guidelines as an increase in serum creatinine (Scr) by ≥ 0.3 mg/dl (≥ 26.5 μmol/l) from baseline within 48 h